Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03568019
Other study ID # STU 092013-001
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date November 26, 2013
Est. completion date February 15, 2026

Study information

Verified date May 2024
Source University of Texas Southwestern Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

PET has an established role in the initial staging of patients with newly diagnosed lung and gastrointestinal tumors.PET avidity is described with both maximum and mean standardized uptake values.Malignant cells have increased activity on PET, defined as the standardized uptake value (SUV), with increased uptake of FDG in tumor due to elevated levels of GLUT receptors, elevated intracellular levels of hexokinase and increased rates of glycolysis. However, there is a subset of patients with lung and gastrointestinal tumors that are not PET avid.These patients may present with clinically and systemically aggressive disease with a declining performance status and/or weight loss.


Description:

This study will be a retrospective review of patients in the tumor registry with lung and gastrointestinal tumors, not limited to but including small and non-small cell lung cancers, stomach cancer, small intestinal cancer, colon cancer, rectal cancer, liver and intrahepatic bile duct cancers, gallbladder and extrahepatic bile duct cancers, and pancreatic cancer. There will be a maximum of 10,000 charts/records that will be reviewed to compile the data. Data to be collected will include patients' name, medical record number, date of birth, race, ethnicity, gender, medical history, medications, vital and performance status, vital signs including weight and body mass index, date of cancer diagnosis, clinical and pathologic stage, pathology, treatment course, prior treatment, location of primary lesion, and smoking history. CT and PET findings to be reviewed include the number of involved lymph nodes, size of primary tumor, average/maximum PET avidity in both the primary tumor and involved lymph nodes.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 10000
Est. completion date February 15, 2026
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: Patients with histologically proven lung and gastrointestinal cancers, stages I-IV with PET and/or CT within 6 weeks of diagnosis. Exclusion Criteria: There will be no absolute exclusion criteria as long as the inclusion criteria have been met.

Study Design


Intervention

Other:
Retrospective study
No subjects will be contacted or recruited. All data will be acquired retrospectively.

Locations

Country Name City State
United States UT Southwestern Medical Centre Dallas Texas

Sponsors (1)

Lead Sponsor Collaborator
University of Texas Southwestern Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary A retrospective review to determine if PET can be used to identify cachexia-inducing lung and gastrointestinal tumors The goal of this assessment is to identify patients with lung and gastrointestinal tumors and collect the data on tumor stage location, histology, PET avidity, and weight loss/performance status so that it will be possible to correlate SUV values associated with cachexia by using CTCAE version 4.0 to collect and log AE and SAE related to cachexia. 10 years
See also
  Status Clinical Trial Phase
Withdrawn NCT03245658 - The Effect of Cannabis in Pancreatic Cancer Phase 2
Withdrawn NCT04034745 - Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain
Recruiting NCT04136249 - Improvement of Neuromuscular Function, Fatigue and Quality of Life by Optimizing Muscle Building and Nutrition in Colorectal Cancer: a Pilot Study N/A
Recruiting NCT03556748 - WB-EMS and Nutrition in Patients With Hematological Malignancies N/A
Completed NCT03283488 - Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care. Phase 2
Suspended NCT04001010 - Safety and Efficacy of Inhaled Synthetic THC/CBD for Improving Physical Functioning and for Modulating Cachexia Progression in Patients With Advanced Cancer and Associated Cachexia Phase 3
Recruiting NCT04406662 - Routine Evaluation of People Living With Cancer
Completed NCT03524755 - Physical Exercise for Patients Who Suffer From Weight Loss Due to Head and Neck Cancer Undergoing Medical Treatment N/A
Completed NCT03316157 - Exercise and Nutritional Rehabilitation in Patients With Cancer N/A
Completed NCT03012139 - Cancer-Associated Muscle Atrophy and Weakness: An Investigation of Etiology
Recruiting NCT03789136 - The Effect of Colon Cancer on Muscle Gene Expression, Body Composition, Muscle Function, and Muscle Metabolism
Completed NCT03263520 - Impact of the Use of Nandrolone on the Treatment of Malnutrition Induced by Cancer N/A
Completed NCT04161794 - Multimodal Intervention for Patients With Non-small Cell Lung Cancer N/A
Completed NCT03743064 - A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Phase 3
Completed NCT03743051 - A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Phase 3
Recruiting NCT04353063 - Muscle Wasting in Children and Adolescents With Cancer N/A
Completed NCT04131426 - Evaluating the Combined Intervention of Nutritional Supplementation (Remune) and Exercise in Patients With Cancer Cachexia Phase 1